CalRx, California’s initiative to produce affordable insulin, is experiencing major setbacks. Initially promised for delivery by 2024 by Governor Newsom, the program now has no definitive timeline. Civica, Inc., the contracted manufacturer, has yet to begin clinical trials or apply for FDA approval, essential steps before the insulin can reach consumers. The American Diabetes Association projects availability could be delayed until as late as 2030, leaving over 3.5 million Californians with diabetes waiting for more affordable treatment options. (CalMatters)